Indian drug makers to drop Bradley bids

Count Indian drug makers Ranbaxy and Dr. Reddy's out of the bidding for Bradley Pharmaceuticals. The two companies entered non-binding bids of around $250 million to $300 million--much lower than those submitted by U.S. firms.

Bradley began accepting bids last month, saying it would definitely pursue a buyout. The company's market cap is around $330 million.

- read the report from India's Business Standard

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.